Logotipo del repositorio
 

Long-term efficacy and safety of sensor augmented insulin pump therapy with low-glucose suspend feature in patients with type 1 diabetes

Vista sencilla de ítem
dc.contributor.authorGómez Gómez, Ana María
dc.contributor.authorMarín Carrillo, Lisseth Fernanda
dc.contributor.authorMuñoz Velandia, Oscar Mauricio
dc.contributor.authorRondón Sepúlveda, Martín Alonso
dc.contributor.authorArévalo Correa, Carol M.
dc.contributor.authorHenao Carrillo, Diana Cristina
dc.contributor.authorCuervo Díaz, María Camila
dc.contributor.authorMora Garzón, Edwin Ronald
dc.contributor.corporatenamePontificia Universidad Javeriana. Facultad de Medicina. Departamento de Epidemiología Clínica y Bioestadística
dc.contributor.corporatenamePontificia Universidad Javeriana. Facultad de Medicina. Departamento de Medicina Interna. Enfermedades Crónicas del Adultospa
dc.coverage.cityBogotá (Colombia)spa
dc.coverage.spatialColombiaspa
dc.date.accessioned2020-03-30T15:12:48Z
dc.date.accessioned2020-04-15T13:25:52Z
dc.date.available2020-03-30T15:12:48Z
dc.date.available2020-04-15T13:25:52Z
dc.date.created2017-02-01
dc.description.abstractenglishBACKGROUND: Literature supports short-term efficacy and safety of Sensor Augmented Insulin Pump (SAP) therapy in patients with type 1 diabetes (T1D). However, no data are available showing long-term outcomes. Our study describes the long-term outcomes of SAP therapy with low-glucose suspend feature (SAP+LGS) in hypoglycemia in a Colombian population with T1D and hypoglycemia. METHODS: A cohort study was conducted with T1D patients receiving SAP+LGS therapy who initiated this therapy because of hypoglycemia at San Ignacio University Hospital diabetes center in Bogotá, Colombia. Glycated hemoglobin (A1c) was assessed at least every 6 months, severe hypoglycemia (SH) and hypoglycemia unawareness (HU) incidence yearly. Adherence to therapy was also evaluated. RESULTS: One hundred eleven patients were included in the analysis. Total daily insulin dose was reduced during follow-up (mean difference -0.22 U/kg; 95% confidence interval [CI] -0.18 to -0.26; P < 0.001). A1c levels were reduced from a baseline value of 8.8% ± 1.9% to 7.5% ± 1.0% at 5 months (mean difference -1.3%; 95% CI -1.09 to -1.50; P < 0.001) and 7.1% ± 0.8% (mean difference -1.7%; 95% CI -1.59 to -1.90; P < 0.001) at the end of follow-up (47 months on average). The incidence of SH and HU episodes decreased significantly since the first year, and this effect was maintained over time (P < 0.001). CONCLUSIONS: SAP+LGS therapy in T1D patients with hypoglycemia led to a significant and sustained decrease in A1c during long periods of follow-up, as well as a significant reduction in SH and HU. Future randomized clinical trials are desired.spa
dc.description.comunidadPacientes con diabetes tipo 2 recibiendo terapia SAP+LGSspa
dc.description.paginas109-114spa
dc.description.quartilescopusQ1spa
dc.description.quartilewosQ1spa
dc.description.tipoarticuloArtículo originalspa
dc.formatPDFspa
dc.format.mimetypeapplication/pdfspa
dc.format.soportePapel / Electrónicospa
dc.identifierhttps://www.liebertpub.com/doi/abs/10.1089/dia.2016.0332?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&journalCode=diaspa
dc.identifier.doihttps://doi.org/10.1089/dia.2016.0332spa
dc.identifier.issn1520-9156 / 1557-8593 (Electrónico)spa
dc.identifier.urihttp://hdl.handle.net/10554/47941
dc.languagespaspa
dc.rights.licenceAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.sourceDiabetes Technology & Therapeutics; Vol. 19 Núm. 2 (2017)spa
dc.subject.keywordContinuous glucose monitoringspa
dc.subject.keywordContinuous subcutaneous insulin infusionspa
dc.subject.keywordHypoglycemia unawarenessspa
dc.subject.keywordLong-term follow-upspa
dc.subject.keywordLow-glucose suspend functionspa
dc.subject.keywordSensor augmented insulin pump therapyspa
dc.subject.keywordSevere hypoglycemiaspa
dc.subject.keywordType 1 diabetesspa
dc.titleLong-term efficacy and safety of sensor augmented insulin pump therapy with low-glucose suspend feature in patients with type 1 diabetesspa
dc.typeinfo:eu-repo/semantics/article
dc.type.hasversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.localArtículo de revistaspa

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
DiabetesTechTher19n2.pdf
Tamaño:
184.01 KB
Formato:
Adobe Portable Document Format
Descripción:
Artículo
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
2.54 KB
Formato:
Plain Text
Descripción:
Descargar

Colecciones

Artículos
Artículos